News

Vanderbilt University researchers have partnered with Mapp Biopharmaceutical Inc. to develop new human antibody therapies for people exposed to the deadly Ebola and Marburg viruses.

Bucket showers. No internet. Generator-based power, so when the fuel ran out so did the electricity. Those were factors that Erik-one of CDC’s disease detectives recently deployed to Liberia-expected during his thirty-day trip abroad. But it was the unrelenting grip Ebola had on everyday life that took him by surprise, and tugged at his heart.

For the first time ever, the World Health Organization (WHO) is leading the health response to five major humanitarian crises at the same time. More than 60 million people, from West Africa to Iraq, urgently require a wide range of healthcare services.

The Ebola outbreak could claim hundreds of thousands of lives and infect more than 1.4 million people by the end of January, according to a statistical forecast released this week by the Centers for Disease Control and Prevention (CDC).

Bacillus anthracis bacteria have very efficient machinery for injecting toxic proteins into cells, leading to the potentially deadly infection known as anthrax. A team of MIT researchers has now hijacked that delivery system for a different purpose: administering cancer drugs.